Medical research and development (R&D) differs from other R&D because of a unique linkage between output and input markets for medical products: potential consumers of existing medical products are also potential subjects in clinical trials required to develop new products. Therefore, an increase in the quality or reduction in the price of an existing treatment reduces the incentive of patients to participate in trials of new treatments. We provide evidence of this linkage, which we label the “subject supply effect,” by showing that a breakthrough HIV/AIDS treatment led to a sharp drop in the supply of trial subjects after the introduction of the treatment in 1996. The subject supply effect has important positive implications for how policies such as recent insurance expansions affect the rate of medical R&D and normative implications for whether subjects ought to be compensated for enrolling in clinical trials, an ethically controversial practice.

More on this topic

BFI Working Paper·Sep 18, 2025

The Five Shanghai Themes

Harald Uhlig
Topics: Economic Mobility & Poverty, Energy & Environment, Financial Markets, Health care
BFI Working Paper·Aug 13, 2025

Post-Roe Planning: The Effect of Dobbs v. Jackson on Contraceptive and Sterilization Choices

Yana Gallen and Daisy Lu
Topics: Health care
BFI Working Paper·Aug 7, 2025

Pharmacy Benefit Managers and Vertical Relationships in Drug Supply

Zarek Brot-Goldberg, Catherine Che, and Benjamin Handel
Topics: Health care